This press release contains no financial data or corporate events — it is a clinical evidence summary. No immediate trading action is warranted. Monitor upcoming quarterly earnings for revenue trends and coach network metrics.
Price Chart
Executive Summary
Medifast (MED) issued a press release highlighting OPTAVIA's clinical evidence differentiating its coach-guided metabolic health system from app-only weight loss programs. The release cites published data showing coach-supported participants lost up to 10x more weight and 17x more fat, with 14% visceral fat reduction and 98% lean mass retention over 16 weeks. No financial data, guidance, or material corporate events were disclosed — the release is purely a marketing/educational piece.
Key Facts
- Press release focuses on OPTAVIA's clinical evidence vs. app-only weight loss programs, citing 18 randomized controlled trials and 100+ peer-reviewed publications.
- No financial results, guidance, M&A, product approvals, or other material corporate events were disclosed.
- The release references published data: coach-supported participants lost up to 10x more weight and 17x more fat vs. self-directed efforts.
- OPTAVIA clinical trial showed 14% visceral fat reduction and 98% lean mass retention over 16 weeks.
- Medifast's market cap is ~$140M; analyst consensus is 0% bullish with 4 Hold, 4 Sell, 1 Strong Sell ratings.
Financial Impact
No financial figures disclosed in the press release.
Risk Factors
- Press release may be viewed as a marketing effort with no new financial catalysts.
- Medifast faces significant analyst skepticism (0% bullish consensus) and declining fundamentals not addressed here.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299166 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $11.56 | awaiting T+5 | — | $12.74 (+10.25%) |
Oct 15, 2026 12d ago | Press Release | $12.06 $12.17 | ▲ +0.91% | ▲ +1.93% | $12.74 (+5.68%) |
Oct 6, 2026 21d ago | Press Release | $11.51 $11.67 | ▲ +1.39% | ▲ +1.53% | $12.74 (+10.73%) |
Oct 1, 2026 26d ago | Press Release | $11.43 $11.43 | · 0.00% | ▼ −1.30% | $12.74 (+11.50%) |
Aug 28, 2026 8w ago | Insider Buy | $12.18 $12.63 | ▲ +3.69% | ▲ +3.59% | $12.74 (+4.64%) |
Aug 26, 2026 8w ago | Insider Buy | $12.22 $12.67 | ▲ +3.68% | ▲ +3.80% | $12.74 (+4.30%) |
Aug 21, 2026 9w ago | Insider Buy | $11.95 $12.18 | ▲ +1.92% | ▲ +1.45% | $12.74 (+6.65%) |
Jul 17, 2026 14w ago | 8-K | $10.26 $9.45 | ▼ −7.89% | ▼ −7.21% | $12.74 (+24.22%) |
Jun 1, 2026 21w ago | 8-K | $12.70 $12.10 | ▼ −4.72% | ▼ −1.97% | $12.74 (+0.35%) |
May 26, 2026 21w ago | 8-K | $12.72 $12.36 | ▼ −2.83% | ▼ −4.04% | $12.74 (+0.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers